Haploidentical Stem Cell Transplantation in Neuroblastoma
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Children with primary resistant or relapsed neuroblastoma who do not achieve remission with
conventional chemotherapy have extremely dismal prognosis. A novel treatment strategy
combining tumor targeted radioisotope treatment with metaiodobenzylguanidine (MIBG) and
immunotherapeutic effect of haploidentical stem cell transplantation (haploSCT) followed by
low-dose donor lymphocyte infusions will be piloted. The use of the isotope is aimed to
decrease pre-transplant tumour burden. Reduced intensity conditioning containing Fludarabine,
Thiotepa and Melfalan will enable sustained engraftment as well as will serve as additional
anti-tumor treatment. A prompt natural killer (NK)-cell mediated tumour control may be
achieved by haploidentical stem cell transplantation. The investigators hypothesize that
tumour cells potentially evading NK-cell mediated immunity may be targeted by infused donor
T-cells and eliminated by either MHC-dependent manner or through a bystander effect. The
possible graft versus tumor effect will be evaluated in children with therapy resistant
neuroblastoma.